Silexon is founded and managed by interdisciplinary experts equipped with both biopharmaceutical and computer science/machine learning domain knowledge. Silexon aims to create an open AI platform for strategic collaboration in order to facilitate data-driven life science research and empower drug R&D process, and ultimately provide patients with greater access to innovative drugs for unmet medical needs. Since incorporation, Silexon has identified several lead compounds with collaborators and through in house programs for various targets such as kinase, GPCR and others. Silexon has also been in close discussions with several multinational pharmaceutical companies regarding potential collaboration on drug repurposing, drug discovery/virtual HTS and protein yield increase.